McKesson Corporation (MCK)
McKesson Corporation (MCK) carries a ŷRobot AI score of 70 out of 100. The model's fair value estimate is $1,009.71, 3.3% above the last close of $977.75. The chart signal reads Bearish.
| Metric | MCK |
|---|---|
| AI score | 70 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $1,009.71 |
| Upside to fair value | 3.3% |
| Previous close | $977.75 |
| P/E | 22.91 |
| Price / sales | 0.25 |
| Market cap | $111.43B |
| EPS | 37.27 |
| Revenue growth | 12.8% |
| 1-year price change | 25.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about MCK
Is MCK overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates McKesson Corporation (MCK) at $1009.71 against a last close of $977.75, implying 3.3% upside to the model's estimate.
Is MCK's chart signal bullish or bearish?
The chart-signal model classifies MCK as Neutral as of Oct 14, 2026, with a signal score of -0.09 on a -1 to 1 scale.
What is MCK's ŷRobot AI score?
MCK scores 70 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is MCK stock expensive on P/E and P/S?
MCK trades at 22.9 times earnings and 0.3 times sales as of Oct 14, 2026.
What does MCK's seasonal forecast show?
ŷRobot's seasonal forecast curve for MCK reads +3.2% at 30 days, +10.2% at 90 days, and +25.6% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is MCK growing?
McKesson Corporation's revenue growth is +12.8% and free-cash-flow growth is +2.5% on the latest reported figures.
MCK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.